title: Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
abstract: Cytochrome P450 2J2 plays a significant role in the epoxidation of arachidonic acid to signaling molecules important in cardiovascular events. CYP2J2 also contributes to drug metabolism and is responsible for the intestinal clearance of ebastine. However, the interaction between arachidonic acid metabolism and drug metabolism in cardiac tissue, the main expression site of CYP2J2, has not been examined. Here we investigate an adult-derived human primary cardiac cell line as a suitable model to study metabolic drug interactions (inhibition and induction) of CYP2J2 in cardiac tissue. The primary human cardiomyocyte cell line demonstrated similar mRNA-expression profiles of P450 enzymes to adult human ventricular tissue. CYP2J2 was the dominant isozyme with minor contributions from CYP2D6 and CYP2E1. Both terfenadine and astemizole oxidation were observed in this cell line, whereas midazolam was not metabolized suggesting lack of CYP3A activity. Compared with recombinant CYP2J2, terfenadine was hydroxylated in cardiomyocytes at a similar K(m) value of 1.5 μM. The V(max) of terfenadine hydroxylation in recombinant enzyme was found to be 29.4 pmol/pmol P450 per minute and in the cells 6.0 pmol/pmol P450 per minute. CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects. Of the 14 compounds tested for CYP2J2 induction, only rosiglitazone increased mRNA expression, by 1.8-fold. This cell model can be a useful in vitro model to investigate the role of CYP2J2-mediated drug metabolism, arachidonic acid metabolism, and their association to drug induced cardiotoxicity.
authors.affiliation: Department of Medicinal Chemistry (E.A.E., R.K., J.P.J., R.A.T.) and Division of Cardiothoracic Surgery, University of Washington, Seattle, Washington (N.A.M.).
authors.forename: Eric A
authors.initials: EA
authors.lastname: Evangelista
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Kaspera
authors.forename: Nahush A
authors.initials: NA
authors.lastname: Mokadam
authors.forename: J P
authors.initials: JP
authors.lastname: Jones
authors.forename: Rheem A
authors.initials: RA
authors.lastname: Totah
mesh_terms: D002478:Cells, Cultured; D000090762:Cytochrome P-450 CYP2J2; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D004347:Drug Interactions / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006728:Hormones / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D015262:Xenobiotics / Q000494:pharmacology
chemical_list: C000717350:CYP2J2 protein, human; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D006728:Hormones; D012333:RNA, Messenger; D015262:Xenobiotics; D003577:Cytochrome P-450 Enzyme System; D000090762:Cytochrome P-450 CYP2J2
references.citation: FASEB J. 2011 Feb;25(2):703-13
references.pmid: 21059750
references.citation: Pharmacogenet Genomics. 2007 Sep;17(9):731-42
references.pmid: 17700362
references.citation: Pharmacol Ther. 2012 May;134(2):180-8
references.pmid: 22269465
references.citation: J Biol Chem. 1996 Feb 16;271(7):3460-8
references.pmid: 8631948
references.citation: J Mol Cell Cardiol. 2009 Jan;46(1):67-74
references.pmid: 18973759
references.citation: J Biol Chem. 1997 May 9;272(19):12551-9
references.pmid: 9139707
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):298-304
references.pmid: 11752129
references.citation: Arch Biochem Biophys. 2003 Aug 1;416(1):17-24
references.pmid: 12859977
references.citation: Mol Pharmacol. 1997 Jun;51(6):931-43
references.pmid: 9187259
references.citation: Drug Metab Dispos. 2007 Apr;35(4):682-8
references.pmid: 17220242
references.citation: J Cardiovasc Transl Res. 2013 Feb;6(1):22-30
references.pmid: 23229562
references.citation: Pharmacogenet Genomics. 2008 Jan;18(1):45-51
references.pmid: 18216721
references.citation: Adv Pharmacol. 2010;60:27-59
references.pmid: 21081214
references.citation: Biochem Soc Trans. 2010 Aug;38(4):1037-45
references.pmid: 20659000
references.citation: Drug Metab Dispos. 2002 Nov;30(11):1240-5
references.pmid: 12386130
references.citation: Am J Physiol Cell Physiol. 2007 Mar;292(3):C996-1012
references.pmid: 16987999
references.citation: Drug Metab Dispos. 2006 Nov;34(11):1793-7
references.pmid: 16896065
references.citation: Biochem Pharmacol. 2011 Sep 15;82(6):681-91
references.pmid: 21726541
references.citation: Drug Metab Dispos. 2012 Nov;40(11):2204-11
references.pmid: 22912432
references.citation: J Biol Chem. 1964 Jul;239:2370-8
references.pmid: 14209971
references.citation: Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H37-46
references.pmid: 19429816
references.citation: Circ Res. 2004 Sep 3;95(5):506-14
references.pmid: 15256482
references.citation: Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5597-601
references.pmid: 1829523
references.citation: PPAR Res. 2010;2010:325183
references.pmid: 20981297
references.citation: Trends Pharmacol Sci. 2007 Jan;28(1):32-8
references.pmid: 17150260
references.citation: Drug Metab Dispos. 2012 May;40(5):943-51
references.pmid: 22328583
references.citation: J Physiol. 2001 Dec 15;537(Pt 3):811-27
references.pmid: 11744757
references.citation: Br J Clin Pharmacol. 2001 Feb;51(2):133-42
references.pmid: 11259984
references.citation: PLoS One. 2010 Dec 14;5(12):e15666
references.pmid: 21179487
references.citation: Arch Biochem Biophys. 2009 Sep;489(1-2):82-91
references.pmid: 19464254
references.citation: Mol Pharmacol. 2010 Jun;77(6):987-94
references.pmid: 20194533
references.citation: Physiol Rev. 2002 Jan;82(1):131-85
references.pmid: 11773611
references.citation: Vascul Pharmacol. 2013 Apr;58(4):326-33
references.pmid: 23268359
references.citation: Trends Cardiovasc Med. 2006 Aug;16(6):204-8
references.pmid: 16839864
references.citation: Pflugers Arch. 2010 May;459(6):881-95
references.pmid: 20224870
references.citation: Curr Drug Metab. 2006 May;7(4):375-88
references.pmid: 16724927
references.citation: Br J Pharmacol. 2000 Aug;130(8):1745-52
references.pmid: 10952662
references.citation: Mol Pharmacol. 2004 Mar;65(3):730-43
references.pmid: 14978252
references.citation: J Biol Chem. 2004 May 28;279(22):22848-56
references.pmid: 15026419
references.citation: Pharmacogenet Genomics. 2008 Jun;18(6):535-43
references.pmid: 18496133
references.citation: Steroids. 2006 Oct;71(10):849-56
references.pmid: 16842832
references.citation: Biochemistry. 2001 Apr 24;40(16):5018-31
references.pmid: 11305918
references.citation: Arch Biochem Biophys. 2007 Aug 15;464(2):155-68
references.pmid: 17470359
references.citation: Circulation. 2004 Oct 12;110(15):2132-6
references.pmid: 15466638